Skip to content

2-Chloro-3-Hydrazinylquinoxaline Mitigates Doxorubicin-Induced Hepatic Inflammation in Rats.

Nov 2026 · Clinical Laboratory · Vol 72 11, pp. 2590-2604 · 0 citations
Medicine

Abstract

Background

In this research, 2-chloro-3-hydrazinylquinoxaline (CHQ) was evaluated for hepatoprotection and mechanism of action against the hepatotoxicity and liver inflammation in rats induced by the drug doxorubicin (DOX).

Methods

Twenty-four male Wistar rats were split into four groups (n = 6 per group): normal control, DOX-only (15 mg/kg, i.p. day 6), and two treatment groups (daily oral CHQ 30 mg/kg or 60 mg/kg for 28 days). Blood biochemical parameters and liver and tissue examinations for oxidative markers and inflammatory mediators were performed. Histopathology was done to check hepatic tissue changes (H&E).

Results

DOX treatment produced significant systemic toxicity, as evidenced by reduced body weight, hepatomagaly, and elevated serum liver enzyme levels compared with the control group (p < 0.05). It caused significant oxidative stress, leading to higher malondialdehyde (MDA) levels and lower glutathione, superoxide dismutase, and catalase levels (p < 0.05). Moreover, DOX triggered elevated levels of pro-inflammatory cytokines, activation of nuclear factor kappa-β, and decreased activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (p < 0.001). On H&E sections, intense necrosis and leukocyte infiltration were present. Conversely, co-treatment with CHQ, in a dose-dependent manner, significantly reverses these changes (p < 0.05). It acts as a supplement to antioxidant mechanisms, reduces serum enzyme leakage, and regulates pro-inflammatory cytokines and signaling pathways, with a dose of 60 mg/kg producing near-mild liver histology.

Conclusions

CHQ was observed to be a significant protective agent against DOX-induced hepatotoxicity, with a dose-dependent effect, increasing antioxidant defense mechanisms, and decreasing DOX-mediated inflammatory responses, thereby making it a promising agent for the prevention of DOX-induced liver injury.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.